Sustainability and Durability of Culture Conversion in Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex Lung Disease (MAC-LD) in the CONVERT Study

被引：0

作者：

Griffith, D. E. ^{[1
]}

Thomson, R. ^{[2
]}

Addrizzo-Harris, D. J. ^{[3
]}

Field, S. K. ^{[4
]}

van Ingen, J. ^{[5
]}

Wallace, R. J., Jr. ^{[1
]}

Coulter, C. ^{[6
]}

Mange, K. ^{[7
]}

Nezamis, J. ^{[7
]}

Winthrop, K. L. ^{[8
]}

机构：

[1] Univ Texas Hlth Sci Ctr Tyler, Tyler, TX USA

[2] Univ Queensland, Gallipoli Med Res Inst, Brisbane, Qld, Australia

[3] NYU, Sch Med, Div Pulm Crit Care & Sleep Med, New York, NY USA

[4] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada

[5] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands

[6] Pathol Queensland, Queensland Mycobacterium Reference Lab, Brisbane, Qld, Australia

[7] Insmed Inc, Bridgewater, NJ USA

[8] OHSU PSU Sch Publ Hlth, Portland, OR USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A7359

引用

页数：2

共 45 条

[1] Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease: Effect of Baseline Amikacin and Clarithromycin Susceptibility on Culture Conversion
Winthrop, K. L.
Flume, P. A.
Thomson, R.
Brown-Elliott, B. A.
Wallace, R. J., Jr.
Griffith, D. E.
Pennings, L. J.
Coulter, C.
Syrmis, M.
Pandey, S.
Yuen, D.
Mange, K.
van Ingen, J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[2] EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)
Winthrop, Kevin
Eagle, Gina
Morimoto, Kozo
Castellotti, Paola Francesca
O'Donnell, Anne
Ruoss, Stephen
Aksamit, Timothy
Nezamis, James
Griffith, David
CHEST, 2018, 154 (04) : 182A - 183A
[3] Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)
Griffith, David E.
Eagle, Gina
Thomson, Rachel
Aksamit, Timothy R.
Hasegawa, Naoki
Morimoto, Kozo
Addrizzo-Harris, Doreen J.
O'Donnell, Anne E.
Marras, Theodore K.
Flume, Patrick A.
Loebinger, Michael R.
Morgan, Lucy
Codecasa, Luigi R.
Hill, Adam T.
Ruoss, Stephen J.
Yim, Jae-Joon
Ringshausen, Felix C.
Field, Stephen K.
Philley, Julie V.
Wallace, Richard J., Jr.
van Ingen, Jakko
Coulter, Chris
Nezamis, James
Winthrop, Kevin L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (12) : 1559 - 1569
[4] AN OPEN-LABEL EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)
Winthrop, Kevin
Morimoto, Kozo
Castellotti, Paola Francesca
Yim, Jae-Joon
Ruoss, Stephen
van Ingen, Jakko
Coulter, Christopher
Mange, Kevin
Nezamis, James
Griffith, David
CHEST, 2019, 156 (04) : 146A - 147A
[5] Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure
Griffith, David E.
Thomson, Rachel
Flume, Patrick A.
Aksamit, Timothy R.
Field, Stephen K.
Addrizzo-Harris, Doreen J.
Morimoto, Kozo
Hoefsloot, Wouter
Mange, Kevin C.
Yuen, Dayton W.
Ciesielska, Monika
Wallace, Richard J., Jr.
van Ingen, Jakko
Brown-Elliott, Barbara A.
Coulter, Chris
Winthrop, Kevin L.
CHEST, 2021, 160 (03) : 831 - 842
[6] RELATIONSHIP BETWEEN IN VITRO CLARITHROMYCIN SUSCEPTIBILITY AND SPUTUM CULTURE CONVERSION WITH ADD-ON AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT OF REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
Griffith, David
Eagle, Gina
Wallace, Richard
Brown-Elliott, Barbara
Van Ingen, Jakko
Pennings, Lian
Berry, Brooke
Pandey, Sushil
Coulter, Christopher
Syrmis, Melanie
Morimoto, Kozo
Hasegawa, Naoki
CHEST, 2018, 154 (04) : 109A - 110A
[7] Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients
Griffith, D. E.
Eagle, G.
Thomson, R. M.
Aksamit, T. R.
Hasegawa, N.
Morimoto, K.
Addrizzo-Harris, D. J.
O'Donnell, A. E.
Marras, T. K.
Flume, P. A.
Loebinger, M. R.
Morgan, L. C.
Castellotti, P. F.
Hill, A. T.
Ruoss, S. J.
Yim, J. J.
Ringshausen, F. C.
Field, S. K.
Nezamis, J.
Winthrop, K. L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[8] Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection
Zhang, Yang
Hill, Adam T.
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (06) : 737 - 744
[9] Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
Winthrop, K. L.
Eagle, G.
Thomson, R. M.
Aksamit, T. R.
Hasegawa, N.
Morimoto, K.
Addrizzo-Harris, D. J.
O'Donnell, A. E.
Marras, T. K.
Flume, P. A.
Loebinger, M. R.
Morgan, L. C.
Codecasa, L. R.
Hill, A. T.
Ruoss, S. J.
Yim, J. J.
Ringshausen, F. C.
Field, S. K.
Nezamis, J.
Griffith, D. E.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[10] THE RELATIONSHIP BETWEEN CULTURE CONVERSION AND IMPROVEMENT IN 6-MINUTE WALK TEST DISTANCE IN THE CONVERT STUDY EVALUATING AMIKACIN LIPOSOME INHALATION SUSPENSION FOR REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
Mange, Kevin
Roberts, Kevin
Zandvliet, Anthe
Witjes, Han
Neve, Marta
Lovern, Mark
CHEST, 2019, 156 (04) : 1126A - 1126A

← 1 2 3 4 5 →